Core Viewpoint - Shandong Pharmaceutical Glass (600529.SH) announced the termination of its original controlling shareholder restructuring and finalized a private placement plan to raise 3.235 billion yuan, with the China National Pharmaceutical Group (Sinopharm) set to become the new controlling shareholder, changing the actual controller from the Yiyuan County Finance Bureau of Shandong Province to the State-owned Assets Supervision and Administration Commission of the State Council [1][5][10] Group 1: Company Overview - Shandong Pharmaceutical Glass was established in 1993 with a registered capital of 664 million yuan and is located in Zibo City, Shandong Province [1] - The company is a leading player in the pharmaceutical glass industry, mastering core processes such as borosilicate molded bottles and borosilicate tubes, with product quality at the forefront [1][5] Group 2: Restructuring and Capital Cooperation - The termination of the restructuring was due to a long-anticipated capital cooperation adjustment involving Shandong Luzhong Investment Co., Ltd. (Luzhong Investment), which was the previous controlling shareholder [3][9] - In June 2025, Sinopharm International and its Hong Kong subsidiary signed an investment cooperation agreement with Luzhong Investment, aiming to acquire 51% of Luzhong Investment's shares to indirectly participate in Shandong Pharmaceutical Glass's operations [3][8] Group 3: Private Placement Details - The company plans to issue shares to specific investors to raise no more than 3.235 billion yuan, with a share price set at 16.25 yuan per share, representing 80% of the average stock price over the previous 20 trading days [4][9] - The issuance will not exceed 19,908,420 shares, accounting for 30% of the company's total share capital before the issuance [4][9] Group 4: New Shareholders and Control Changes - The subscribers for the new shares include Sinopharm International and its affiliate Shandong Yaoxin Health Industry Co., Ltd., with Sinopharm International set to acquire 15,607,300 shares and Shandong Yaoxin 4,307,690 shares [4][10] - Post-issuance, Sinopharm International and Shandong Yaoxin will hold a combined 199 million shares, representing 23.08% of the total share capital, making Sinopharm International the controlling shareholder [4][10] Group 5: Future Directions and Funding Utilization - The net proceeds from the fundraising will be used to supplement working capital, focusing on three main development directions: increasing investment in technological innovation, promoting industrial specialization integration, and leveraging Sinopharm International's global network to accelerate international certification processes [5][10] - This collaboration is expected to enhance the company's overall competitiveness and facilitate its transformation into a technology-driven international enterprise [5][10] Group 6: Financial Performance - For the first three quarters of 2025, Shandong Pharmaceutical Glass reported revenue of 3.401 billion yuan, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 542 million yuan, down 24.7% [6][11] - As of the end of September 2025, the company's total assets amounted to 9.882 billion yuan, with total liabilities of 1.733 billion yuan and total net assets of 8.149 billion yuan [6][11]

山东药玻筹划超一年的控股股东重组，最终宣告终止。不过，国药集团对山东药玻的青睐并未改变，转 为直接向上市公司定增以实现入主。 1月14日，山东药玻发布公告称，拟定增募资不超32.35亿元，扣除发行费用后的募集资金净额将全部用 于补充流动资金。 本次向特定对象发行股票的发行对象，为中国国际医药卫生有限公司（以下简称"国药国际"）、山东耀 新健康产业有限公司（以下简称"山东耀新"），其中山东耀新为国药国际全资子公司国药国际香港有限 公司，在境内注册的全资子公司。 本次发行后，国药国际、山东耀新将合计持有山东药玻1.99亿股股票，占本次发行后公司总股本的 23.08%，国药国际成为山东药玻的控股股东，实际控制人为国药集团，最终控制人为国务院国资委。 值得一提的是，本次与此前推进的通过山东药玻控股股东山东鲁中投资有限责任公司（以下简称"鲁中 投资"）的重组方式不同。2025年1月，山东药玻公告称，沂源县人民政府与国药国际筹划公司控股股东 鲁中投资的重组事宜，可能涉及鲁中投资的控股股东变更，从而导致山东药玻间接控股股东的变更。 山东药玻方面表示，1月13日，公司收到鲁中投资的《通知函》显示，本次合作自启动以来，鲁中投 ...

山东药玻（600529）筹划超一年的控股股东重组事宜，最终宣告终止。不过，国药集团对山东药玻的青睐没有改变，转为直接向上市公司定增来实现入主。 1月14日，山东药玻发布公告称，公司拟定增募资不超32.35亿元，扣除发行费用后的募集资金净额将全部用于补充流动资金。 资料显示，山东药玻是我国药用玻璃行业的龙头企业，掌握中硼硅模制瓶、中硼硅拉管等核心工艺。药用玻璃是最重要的药用包装材料之一，相对于其他医 药包装材料，药用玻璃具有透明性、光洁性、阻隔性、化学稳定性、耐温性、相容性、再生性等诸多优良特征，是生物制剂、高端注射剂等领域不可替代的 包装容器。 山东药玻表示，对比国际领先药包材企业，公司产品体系仍有进一步丰富空间，在高端覆膜胶塞、预灌封高端市场份额、全球生产网络布局等方面仍有差 距，研发超前性程度与打造科技型国际化公司目标尚不匹配。本次向特定对象发行股票，募集资金可持续提升科研创新能力和新技术新产品投入力度，在更 本次向特定对象发行股票的发行对象为中国国际医药卫生有限公司（以下简称"国药国际"）、山东耀新健康产业有限公司（以下简称"山东耀新"），其中山 东耀新是国药国际全资子公司国药国际香港在境内注册的全资子 ...